Year: 2024
Finally, Graphene electronic devices available for all
Paragraf, the world’s only mass producer of graphene electronics using transfer-free graphene grown with conventional semiconductor processes, has opened a new online store to enable global access to its unique Graphene-based Field Effect Transistor (“GFET”). GFETs have a wide range of uses in the development of industry, medical, and chemical
Read More
Ventyx Biosciences reports clinical data for its NLRP3 inhibitor portfolio and provides pipeline updates at virtual investor event
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, have provided clinical and pipeline updates during its virtual investor event. “We are excited to announce clinical updates from our novel
Read More
NorthSea Therapeutics initiates Phase 2A trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)
NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other liver-associated metabolic diseases, has announced the dosing of the first patient in its Phase 2a clinical trial of Orziloben (NST-6179) in intestinal failure-associated liver disease (IFALD),
Read More
Resolve Therapeutics announces publication of Lupus clinical trial results
Resolve Therapeutics, a mid-stage clinical development biotechnology company pioneering first-in-class therapies for autoimmune diseases, has announced the publication of results from its phase 2a clinical trial of RSLV-132 in patients with Systemic Lupus Erythematosus (SLE) in Lupus Science & Medicine. The publication entitled "Evaluation of RNase therapy in systemic lupus
Read More
biomodal delivers the 6-base genome with a powerful new multiomic solution, duet evoC
Novel solution distinguishes 5‑methylcytosine (5mC) and 5‑hydroxymethylcytosine (5hmC) revealing unprecedented insights into current and future states of disease using one 5ng DNA sample biomodal, an omics-based life sciences technology and analytics company, has announced it’s delivering the 6-base genome to customers with the launch of duet multiomics solution evoC (duet
Read More